Patent number: 8084457
Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
Type:
Grant
Filed:
September 15, 2004
Date of Patent:
December 27, 2011
Assignees:
Lead Discovery Center GmbH, Bayer Pharma AG
Inventors:
Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltán Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Müller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
Publication number: 20080207677
Abstract: The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.
Type:
Application
Filed:
January 2, 2006
Publication date:
August 28, 2008
Applicant:
GPC BIOTECH AG
Inventors:
Stefan Muller, Wilfried Schwab, Bert Klebl, Doris Hafenbradl, Edmund Hoppe, Zoltan Horvath, Gyorgy Keri, Zoltan Varga, Laszlo Orfi, Jeno Marosfalvi, Gerhard Muller